Potential New Treatment for Advanced HCC Went Through Successful Phase 1 and Phase 2 Studies
31/07/2019
Potential New Treatment for Advanced HCC Went Through Successful Phase 1 and Phase 2 Studies
31/07/2019
Successful Study on New Drug for Chronic Lymphocytic Leukemia (CLL) Paves Way for Phase 2 Study on Efficacy and Safety of the Selected Dosage
24/07/2019
Successful Study on New Drug for Chronic Lymphocytic Leukemia (CLL) Paves Way for Phase 2 Study on Efficacy and Safety of the Selected Dosage
24/07/2019
Study Shows New Drugs for Hepatitis C Well-Tolerated in Chinese Participants
24/07/2019
Phase 1 Study Shows Effective Antiviral Response of Novel Drug for Hepatitis B Virus (HBV)
24/07/2019
Phase 1 Study Shows Effective Antiviral Response of Novel Drug for Hepatitis B Virus (HBV)
24/07/2019
Immunotherapy Drug Proven More Effective Than Traditional Sorafenib Treatment for HCC Patients
24/07/2019
Immunotherapy Drug Proven More Effective Than Traditional Sorafenib Treatment for HCC Patients
24/07/2019
Potential New Treatment for Advanced HCC Went Through Successful Phase 1 and Phase 2 Studies
24/07/2019
Potential New Treatment for Advanced HCC Went Through Successful Phase 1 and Phase 2 Studies
24/07/2019
[Centre Activity] HKU/QMH Completed NMPA Re-inspection and Received Clinical Trials Accreditation in a Total of 14 Clinical Specialties/Areas
25/06/2019
[Centre Activity] HKU/QMH Completed NMPA Re-inspection and Received Clinical Trials Accreditation in a Total of 14 Clinical Specialties/Areas
25/06/2019
National Medical Products Administration (NMPA, previously called China Food and Drug Administration) visited Queen Mary Hospital on 29th April, 2019 for re-inspection on 14 clinical specialties (including HKU Phase 1 Clinical Trials Centre, cardiology, endocrinology & metabolism, respiratory medicine, hepatobiliary & pancreatic surgery and liver transplantation, obstetrics & gynaecology, haematology & bone marrow transplantation, neurology, nephrology, clinical immunology, orthopaedics & traumatology, gastroenterology & hepatology, oncology and paediatrics & adolescent medicine). The overall inspection result was satisfactory and the said specialties successfully received the continuing accreditation by the NMPA, meaning that the clinical drug trial data from these specialties are acceptable by the NMPA for evaluation of new drug approval applications.
HKU/QMH has been accredited by the NMPA for conducting clinical drug trials in six clinical specialties since 2006. HKU Phase 1 Clinical Trials Centre and seven additional clinical specialties were further accredited in July 2016.
[Centre Activity] Chinese New Year Booth at Queen Mary Hospital
30/01/2019
HKU-CTC set up a Chinese New Year Booth at Queen Mary Hospital on 30th January, 2019 to share the joy and happiness with the public. Information panels with introduction of clinical trials were displayed. Other than that, Dr. Hong, one of the CTC Panda Ambassadors, visited the booth on that day. He gave out red packets and fai-chuns to the supporters. It attracted many visitors to come and learn more about clinical trials. Here are some highlights of the event:
